(MENAFN- GetNews)
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Irritable Bowel Syndrome pipeline constitutes 15+ key companies continuously working towards developing 20+ Irritable Bowel Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Irritable Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Irritable Bowel Syndrome Pipeline Insight, 2025 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Irritable Bowel Syndrome Market.
Some of the key takeaways from the Irritable Bowel Syndrome Pipeline Report:
Companies across the globe are diligently working toward developing novel Irritable Bowel Syndrome treatment therapies with a considerable amount of success over the years.
Irritable Bowel Syndrome companies working in the treatment market are P4 Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and other s, are developing therapies for the Irritable Bowel Syndrome treatment
Emerging Irritable Bowel Syndrome therapies such as - P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others are expected to have a significant impact on the Irritable Bowel Syndrome market in the coming years.
In October 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a healthcare company specializing in gastrointestinal conditions, is set to present new subgroup analysis findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course. The analyses, derived from the primary endpoint of the pivotal Phase III STARS trial, assess the treatment effect of apraglutide based on baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure (SBS-IF). The oral presentation, reveals that apraglutide demonstrated a consistent treatment effect across various subgroups, including gender, age, body weight, region, race, ethnicity, and SBS characteristics, such as remnant bowel length. These results complement the previously reported positive outcomes from the pivotal Phase III trial.
In February 2024, CinPhloro Pharma , part of the CinRx portfolio, is developing CIN-103 as an innovative treatment for irritable bowel syndrome with predominant diarrhea (IBS-D). The company announced that the first participant in its Phase 2 enviva study has been dosed. CIN-103, a novel phloroglucinol formulation designed for long-term use, is a non-opioid small molecule targeting multiple IBS-D mechanisms, including motility, secretion, pain, spasms, and inflammation.
Irritable Bowel Syndrome Overview
Irritable Bowel Syndrome is a chronic, often debilitating, functional gastrointestinal (GI) disorder. It can begin in childhood, adolescence, or adulthood and can resolve unexpectedly for periods throughout an individual's lifespan, recurring at any age. The condition causes recurrent attacks of abdominal pain or discomfort in association with bowel habits. The most important single risk factors are female gender, younger age and preceding gastrointestinal infections.
Get a Free Sample PDF Report to know more about Irritable Bowel Syndrome Pipeline Therapeutic Assessment-
Emerging Irritable Bowel Syndrome Drugs Under Different Phases of Clinical D=1qaevelopment Include:
P4M01: P4Microbiome
BMC426: Biomica
ORP-101: OrphoMed
INVA 8002: Invea Therapeutics, Inc.
RQ-00310941: RaQualia Pharma
RHB-102: RedHill Biopharma Ltd.
Blautix : 4D pharma
Rifamycin: SV-MMX Cosmo Pharmaceuticals
Route of Administration
Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Irritable Bowel Syndrome Pipeline Therapeutics Assessment
Irritable Bowel Syndrome Assessment by Product Type
Irritable Bowel Syndrome By Stage and Product Type
Irritable Bowel Syndrome Assessment by Route of Administration
Irritable Bowel Syndrome By Stage and Route of Administration
Irritable Bowel Syndrome Assessment by Molecule Type
Irritable Bowel Syndrome by Stage and Molecule Type
DelveInsight's Irritable Bowel Syndrome Report covers around 20+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Irritable Bowel Syndrome product details are provided in the report. Download the Irritable Bowel Syndrome pipeline report to learn more about the emerging Irritable Bowel Syndrome therapies
Some of the key companies in the Irritable Bowel Syndrome Therapeutics Market include:
Key companies developing therapies for Irritable Bowel Syndrome are - Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx, and others.
Irritable Bowel Syndrome Pipeline Analysis:
The Irritable Bowel Syndrome pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Irritable Bowel Syndrome with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Irritable Bowel Syndrome Treatment.
Irritable Bowel Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Irritable Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Irritable Bowel Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Irritable Bowel Syndrome drugs and therapies
Irritable Bowel Syndrome Pipeline Market Drivers
Increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, surge in the level of Unhealthy lifestyle are some of the important factors that are fueling the Irritable Bowel Syndrome Market.
Irritable Bowel Syndrome Pipeline Market Barriers
However, complex diagnostic processes, lack of awareness and other factors are creating obstacles in the Irritable Bowel Syndrome Market growth.
Scope of Irritable Bowel Syndrome Pipeline Drug Insight
Coverage: Global
Key Irritable Bowel Syndrome Companies: P4Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others
Key Irritable Bowel Syndrome Therapies: P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others
Irritable Bowel Syndrome Therapeutic Assessment: Irritable Bowel Syndrome current marketed and Irritable Bowel Syndrome emerging therapies
Irritable Bowel Syndrome Market Dynamics: Irritable Bowel Syndrome market drivers and Irritable Bowel Syndrome market barriers
Request for Sample PDF Report for Irritable Bowel Syndrome Pipeline Assessment and clinical trials
Table of Contents
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Comments
No comment